Peer-Reviewed Journal Details
Mandatory Fields
Giersch, A,Boucart, M,Elliott, M,Vidailhet, P
2010
April
Pharmacology & Therapeutics
Atypical behavioural effects of lorazepam: Clues to the design of novel therapies?
Published
()
Optional Fields
Benzodiazepines Lorazepam GABA Perception Memory Imaging Cognition CONVULSIVE STATUS EPILEPTICUS LATENCY AFFERENT INHIBITION RAT HIPPOCAMPAL SLICE HUMAN MOTOR CORTEX EXPLICIT MEMORY HEALTHY-VOLUNTEERS GABA(A) RECEPTORS VISUAL-CORTEX TIME-COURSE PERCEPTUAL INTEGRATION
126
94
108
Aside from their pharmacokinetic properties, e.g. their speed of action and the duration of residual effects, benzodiazepines are still considered as equivalent in terms of their effects on cognition. Here we review evidence suggesting that certain benzodiazepines, especially lorazepam, differ in a number of respects, in particular with respect to their effects on cognition. We focus this review on memory, attention and visual perception, where impairments may be brought about by only a subset of benzodiazepines in spite of their administration at doses inducing similar sedative effects. This precludes an explanation in terms of sedation. Differences in the effects of benzodiazepines have also been found in electrophysiological and animal behavioural studies.These studies are important for therapeutic approaches for two reasons: first, effects of benzodiazepine prescription on cognitive functions will differ according to the benzodiazepine, contrary to what is usually believed. Less straightforwardly are the possible therapeutic implications of specific effects on cognition following treatment with lorazepam. Indeed, the specific effects this drug has on cognition may reveal not only side-effects but also effects of potential therapeutic value. Current research concentrates on a fine scale analysis of the effects of GABA on different sub-types of GABA(A) receptors. We suggest that from looking at what makes lorazepam different in a behavioural sense from other benzodiazepines we may be in a position to design innovative treatments for major aspects of complex disorders, including schizophrenia. (C) 2010 Elsevier Inc. All rights reserved.
DOI 10.1016/j.pharmthera.2010.01.004
Grant Details
Publication Themes